Saturday, 31 October 2026European Markets
ExploreSearch
ViaNews EU

Enterprise Technology

2 articles

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake's BUILD London 2026 conference demonstrated AI capabilities including Cortex functions and agent evaluations as cloud providers compete for European enterprise adoption. HSBC and Lloyds represent financial institutions migrating to cloud AI platforms. Analysts signal continued AI infrastructure investment with Wolfe Research naming Nvidia top pick and Morgan Stanley raising ASML targets 40%.

ViaNews Editorial Team (Europe)•
Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake unveiled production-ready AI tools at BUILD London 2026, including Cortex AI Functions, Notebooks GA, and Agent Evaluations, targeting European enterprises in regulated sectors. The launch mirrors aggressive AI platform expansions by AWS Bedrock, Google Cloud Vertex AI, and Azure AI as cloud vendors compete for enterprise AI workloads. European financial institutions including HSBC, BNP Paribas, and Citigroup are early adopters of embedded agentic capabilities.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com